Subscribe
brexit_istock-531915594_altamira83
altamira83 / iStockphoto.com
17 January 2019Big Pharma

Life sciences lawyers shocked and concerned amid Brexit uncertainty

Lawyers have told LSIPR they are concerned about the continuing UK political uncertainty having a negative impact on life sciences investment and the Unified Patent Court (UPC).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
UK life sciences bodies submit concerns over ‘no deal’ Brexit
12 November 2018   Associations representing the pharmaceutical and biotechnology fields have said that the UK should maintain “close cooperation” with the EU post-Brexit, to ensure that access to safe and effective medicines continues in both markets.
Big Pharma
UK publishes further no-deal Brexit guidance for medicines
8 January 2019   The UK government has published further guidance on the regulation of medicines, medical devices and clinical trials in the event of a no-deal Brexit.
Big Pharma
UK gov to secure extra freight for medicine after no-deal Brexit
27 June 2019   Industry has welcomed the British government’s announcement that it will take steps to secure additional freight capacity to deal with a shortage of pharmaceuticals in the event of a no-deal Brexit.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

More on this story

Big Pharma
UK gov to secure extra freight for medicine after no-deal Brexit
27 June 2019   Industry has welcomed the British government’s announcement that it will take steps to secure additional freight capacity to deal with a shortage of pharmaceuticals in the event of a no-deal Brexit.
Big Pharma
UK publishes further no-deal Brexit guidance for medicines
8 January 2019   The UK government has published further guidance on the regulation of medicines, medical devices and clinical trials in the event of a no-deal Brexit.
Big Pharma
UK life sciences bodies submit concerns over ‘no deal’ Brexit
12 November 2018   Associations representing the pharmaceutical and biotechnology fields have said that the UK should maintain “close cooperation” with the EU post-Brexit, to ensure that access to safe and effective medicines continues in both markets.

More on this story

Big Pharma
UK gov to secure extra freight for medicine after no-deal Brexit
27 June 2019   Industry has welcomed the British government’s announcement that it will take steps to secure additional freight capacity to deal with a shortage of pharmaceuticals in the event of a no-deal Brexit.
Big Pharma
UK publishes further no-deal Brexit guidance for medicines
8 January 2019   The UK government has published further guidance on the regulation of medicines, medical devices and clinical trials in the event of a no-deal Brexit.
Big Pharma
UK life sciences bodies submit concerns over ‘no deal’ Brexit
12 November 2018   Associations representing the pharmaceutical and biotechnology fields have said that the UK should maintain “close cooperation” with the EU post-Brexit, to ensure that access to safe and effective medicines continues in both markets.

More features

Teva fights for re-listing of inhaler patents at US appeals court
CRISPR patents revoked following Nobel Prize winners’ withdrawal
White & Case hires experienced litigator from A&O Shearman
President Trump 2.0: Five major areas to watch
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case